518 related articles for article (PubMed ID: 7513251)
41. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
[TBL] [Abstract][Full Text] [Related]
42. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
[TBL] [Abstract][Full Text] [Related]
43. m-BACOD chemotherapy for intermediate- and high-grade non-Hodgkin's lymphoma.
Liang R; Chiu E; Chan TK; Todd D; Ho F
Cancer Chemother Pharmacol; 1991; 28(2):135-8. PubMed ID: 1711934
[TBL] [Abstract][Full Text] [Related]
44. CHOP-Bleo plus interferon for stage IV low-grade lymphoma.
McLaughlin P; Cabanillas F; Hagemeister FB; Swan F; Romaguera JE; Taylor S; Rodriguez MA; Velasquez WS; Redman JR; Gutterman JU
Ann Oncol; 1993 Mar; 4(3):205-11. PubMed ID: 7682436
[TBL] [Abstract][Full Text] [Related]
45. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
46. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
[TBL] [Abstract][Full Text] [Related]
47. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
48. Treatment and prognosis of orbital non-Hodgkin's lymphomas.
Platanias LC; Putterman AM; Vijayakumar S; Recant W; Weichselbaum RR; Bitran JD
Am J Clin Oncol; 1992 Feb; 15(1):79-83. PubMed ID: 1372464
[TBL] [Abstract][Full Text] [Related]
49. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
Montserrat E; García-Conde J; Viñolas N; López-Guillermo A; Hernández-Nieto L; Zubizarreta A; Maldonado J; Alcalá A; Faura MV; Llorente A; Bladé J; Fontanillas M; Estapé J
Eur J Haematol; 1996 Nov; 57(5):377-83. PubMed ID: 9003479
[TBL] [Abstract][Full Text] [Related]
50. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
[TBL] [Abstract][Full Text] [Related]
51. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
52. [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
Ramírez V P; Ocqueteau T M; Alvarez Z M; Bertín C-M P; Lira V P; Bustos C M; Besa de C P
Rev Med Chil; 2006 Nov; 134(11):1409-16. PubMed ID: 17277854
[TBL] [Abstract][Full Text] [Related]
53. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
54. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Reyes F; Lepage E; Ganem G; Molina TJ; Brice P; Coiffier B; Morel P; Ferme C; Bosly A; Lederlin P; Laurent G; Tilly H;
N Engl J Med; 2005 Mar; 352(12):1197-205. PubMed ID: 15788496
[TBL] [Abstract][Full Text] [Related]
55. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):17-22. PubMed ID: 11163493
[TBL] [Abstract][Full Text] [Related]
56. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
57. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
58. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
[TBL] [Abstract][Full Text] [Related]
60. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
